Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel bone antiresorptive approaches.

Michael W Lark1, Ian E James

  • 1Department of Musculoskeletal Diseases Biology, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA. michael_lark-1@gsk.com

Current Opinion in Pharmacology
|May 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults.

Clinical pharmacology in drug development·2021
Same author

A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.

CNS drugs·2020
Same author

A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor.

Clinical pharmacology in drug development·2019
Same author

TRV0109101, a G Protein-Biased Agonist of the <i>µ</i>-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic Administration.

The Journal of pharmacology and experimental therapeutics·2017
Same author

Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.

Pain·2014
Same author

Biased ligands at G-protein-coupled receptors: promise and progress.

Trends in pharmacological sciences·2014

Inhibiting bone resorption effectively treats bone loss in conditions like osteoporosis. New antiresorptive therapies are being developed to improve upon existing treatments for bone diseases.

Area of Science:

  • Pharmacology
  • Bone Biology
  • Drug Development

Background:

  • Bone resorption inhibition is a proven strategy for managing bone loss in diseases such as postmenopausal osteoporosis.
  • Current therapies have yielded clinical benefits, but there is a need for further advancements.

Purpose of the Study:

  • To explore novel mechanisms for inhibiting bone resorption.
  • To guide the development of improved bone antiresorptive therapies.

Main Methods:

  • Review of current antiresorptive mechanisms.
  • Investigation of emerging therapeutic targets in the pharmaceutical industry.

Main Results:

  • Identification of several novel antiresorptive mechanisms.

Related Experiment Videos

  • Potential for improved therapeutic strategies in bone disease management.

    • Conclusions:

    • Continued research into novel antiresorptive mechanisms is crucial.
    • The pharmaceutical industry is actively pursuing innovative therapies to enhance bone health and combat bone loss.